Docetaxel is a new taxoid antineoplastic drug widely used for advanced brea
st cancer. Skin and nail toxicity are one of the more frequent nonhematolog
ic adverse reactions. Besides dark pigmentations and Beau's lines, subungua
l hemorrhage, orange discoloration, acute painful paronychia, onycholysis,
subungual hyperkeratosis and transverse loss of the nail plate are describe
d. The type of nail alteration is related with the number of cycles adminis
tered and there are no efficacious preventive measures to avoid its develop
ment. Clinicians should recognize the clinical picture of these adverse nai
l reactions because docetaxel is used for several neoplastic disorders.